Polo-like kinase 1 is essential to DNA damage recovery

References

• Fei P, El-Deiry WS. P53 and radiation responses. Oncogene 2003;22:5774–5783.
   PubMed Web of Science ®Google Scholar
• Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001;4:303–313.
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49–53.
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Ballif BA, Smogorzewska A, et al ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007;316:1160–1166.
   PubMed Web of Science ®Google Scholar
• Shiloh, Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001;11:71–77.
   PubMed Web of Science ®Google Scholar
• Tang J, Erikson RL, Liu X. Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1). Proc Natl Acad Sci USA 2006;103:11964–11969.
   PubMed Web of Science ®Google Scholar
• Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis–cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008;20:650–660.
   PubMed Web of Science ®Google Scholar
• Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996;135:1701–1713.
   PubMed Web of Science ®Google Scholar
• Dai W, Wang Q, Traganos F. Polo-like kinases and centrosome regulation. Oncogene 2002;21:6195–6200.
   PubMed Web of Science ®Google Scholar
• McInnes C, Mazumdar A, Mezna M, et al Inhibitors of polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2006;2:608–617.
   PubMed Web of Science ®Google Scholar
• Lee BH, Amon A. Role of polo-like kinase CDC5 in programming meiosis I chromosome segregation. Science 2003;300:482–486.
   PubMed Web of Science ®Google Scholar
• Petronczki M, Lenart P, Peters JM. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev Cell 2008;14:646–659.
   PubMed Web of Science ®Google Scholar
• Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000;2:672–676.
   PubMed Web of Science ®Google Scholar
• van Vugt MA, Smits VA, Klompmaker R, Medema RH. Inhibition of polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. J Biol Chem 2001;276:41656–41660.
   PubMed Web of Science ®Google Scholar
• Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287–291.
   PubMed Web of Science ®Google Scholar
• Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100:5789–5794.
   PubMed Web of Science ®Google Scholar
• Zhang M, Chen ZC, Liu F, You Y, Liu ZP, Zou P. Effects of PLK1 gene silence on apoptosis of K562 cells. Zhonghua Xue Ye Xue Za Zhi 2005;26:715–718.
   PubMedGoogle Scholar
• Yuan J, Horlin A, Hock B, Stutte HJ, Rubsamen-Waigmann H, Strebhardt K. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997;150:1165–1172.
   PubMed Web of Science ®Google Scholar
• Mito K, Horlin A, Hock B, Stutte HJ, Rubsamen-Waigmann H, Strebhardt K. Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 2005;46:225–231.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang M, Zou P. Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment. Oncology 2008;74:96–103.
   PubMed Web of Science ®Google Scholar
• Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009;10:265–275.
   PubMed Web of Science ®Google Scholar
• Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005;65:2698–2704.
   PubMed Web of Science ®Google Scholar
• Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002;94:1863–1877.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang M, Zou P. Effect of polo-like kinase 1 gene silence on cell cycle and drug resistance in K562/A02 cell. Chin Med J (Engl) 2006;119:605–608.
   Google Scholar
• Marston E, Weston V, Jesson J, et al Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response. Blood 2009;113:117–126.
   PubMed Web of Science ®Google Scholar